

MEET THE EXPERT

ADVANCING HR+/HER2- & HER2-LOW/ULTRALOW METASTATIC BREAST CANCER CARE IN SINGAPORE




TUESDAY
21 JULY 2026



18:00 – 21:00
SGT



NASSIM ROOM
CONRAD SINGAPORE ORCHARD
1 CUSCADEN RD, SINGAPORE



Join leading breast cancer experts for a practical, case-led exchange on where ADCs fit in HR+/HER2- & HER2-low/ultralow mBC.

Scan the QR code to register and secure your place

FACULTY

CHAIRPERSON



Professor Yap Yoon Sim

National Cancer Centre Singapore
Singapore

SPEAKER



Adj A/Professor Samuel Ow

National University Cancer Institute
Singapore

VISITING SPEAKER



Professor Junji Tsurutani

Showa Medical University
Japan

PANELIST



Dr Joline Lim

Curie Oncology
Singapore

PANELIST



Clin Asst Professor Tira Tan

National Cancer Centre Singapore
Singapore

PROGRAMME

Time (SGT)	Topic	Faculty
18:00 – 18:30	Registration and Reception	
18:30 – 18:45	Session Opening Translating ADC Innovation into Real-world Care for Metastatic Breast Cancer: An Overview on T-DXd and Dato-DXd	Professor Yap Yoon Sim
18:45 – 19:25	Targeting TROP2 in HR+ Metastatic Breast Cancer: Emerging Evidence and Clinical Perspectives •Data Presentation for TROPION-Breast01 •TROPION-Breast01: Real-world Applications of Dato-DXd	Professor Junji Tsurutani
19:25 – 19:30	Session 1 Q&A	Professor Junji Tsurutani
19:30 – 19:55	Beyond HER2+ Metastatic Breast Cancer: Navigating the Treatment Landscape of HER2-low/Ultralow mBC: DESTINY-Breast04 and DESTINY-Breast06 Updates	Adj A/Professor Samuel Ow
19:55 – 20:00	Session 2 Q&A	Adj A/Professor Samuel Ow
20:00 – 20:50	Navigating Treatment Choices in Metastatic Breast Cancer: Where Do ADCs Fit? •Case Discussions by Professor Tsurutani and A/Professor Ow •Panel Discussion Q&A	Professor Yap Yoon Sim Professor Junji Tsurutani Adj A/Professor Samuel Ow Dr Joline Lim Clin Asst Professor Tira Tan
20:50 – 21:00	Session Close	Professor Yap Yoon Sim


For healthcare professionals only.



MEET THE EXPERT

ADVANCING HR+/HER2- & HER2-LOW/ULTRALOW

METASTATIC BREAST CANCER CARE IN SINGAPORE



FACULTY



Professor Junji Tsurutani, MD, PhD, is Professor and Director at Showa Medical University's Advanced Cancer Translational Research Institute and Innovative Center of Translational Research and Clinical Science for Cancer Therapy. His work focuses on breast cancer, lung cancer, translational research and clinical trials. He has led or contributed to more than 130 clinical studies, including 25 as Principal Investigator, and serves on key steering committees for ADC-related breast cancer studies, including datopotamab deruxtecan and trastuzumab deruxtecan.



Professor Yap Yoon Sim is Senior Consultant in the Division of Medical Oncology at the National Cancer Centre Singapore and Professor at Duke-NUS Medical School. Her work focuses on clinical and translational breast cancer research, including predictive biomarkers, liquid biopsies and novel therapeutic strategies, and she has served as Principal Investigator on numerous international phase 1-3 clinical trials.



Adj A/Professor Samuel Ow is Senior Consultant Medical Oncologist at the National University Cancer Institute, Singapore, with clinical and research interests in breast cancer and clinical cancer genetics. He is actively involved in breast cancer clinical trials and survivorship care, and serves as an elected Council Member of the Singapore Cancer Society.



Dr Joline Lim is a medical oncologist at Curie Oncology and Visiting Consultant at the National University Cancer Institute, Singapore. Her clinical and research interests focus on female cancers, particularly breast oncology, early-phase clinical trials, novel anti-cancer therapies and biomarker-driven treatment approaches.



Clinical Asst Professor Tira Tan is Senior Consultant Medical Oncologist and Deputy Director of Research at the National Cancer Centre Singapore, and Clinical Assistant Professor at Duke-NUS Medical School. She serves as principal and co-investigator on multiple early- to late-phase breast cancer clinical trials, including studies evaluating datopotamab deruxtecan in early to advanced triple-negative breast cancer.



Daiichi Sankyo Singapore Pte. Ltd.
10 Collyer Quay #07-06/07
Ocean Financial Centre Singapore 049315
Phone: +65 6509 0747



AstraZeneca Singapore Pte. Ltd.
10 Kallang Avenue #12-10
Aperia Tower 2 Singapore 339510
Phone: +65 68124700



Supported by

Singapore Society of Oncology

Event Code SSO-262_BC

Scan the QR code to register and secure your place.



For healthcare professionals only.
The information is for educational purpose only.

SG-10752_ENH_062026
SG-DAT-0030-202606